



The Trendlines Group Portfolio Company IBI Ag Leverages AI-Driven System for Development of De Novo Protein Design Platform for Bioinsecticides

- Cutting-edge AI technology and proprietary biological data for discovery and validation of these new bioinsecticide proteins pave the way for significant expansion of IBI Ag's development pipeline.
- Founded and incubated by Trendlines, IBI Ag has developed a pioneering nanobody-based bioinsecticide platform that adapts human therapeutic antibody technology for sustainable crop protection.

Misgav, Israel – 12 March 2026 – The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, announced that its portfolio company **IBI Ag**, successfully completed its proof of concept (“**POC**”) for the AI-driven platform for De Novo design of novel bioinsecticide proteins. This groundbreaking advancement marks a significant step forward in the quest for innovative, environmentally friendly pest control solutions.

The POC included the design of new proteins that were successfully validated in insect bioassays, demonstrating their efficacy against key agricultural pests. By leveraging cutting-edge AI technology and proprietary biological data, IBI Ag has developed a novel approach to computationally design bioinsecticide proteins that selectively and effectively target pests while aiming to minimize the impact on beneficial insects and the environment.

This innovative methodology represents a paradigm shift in the development of bioinsecticides, offering a faster and more efficient path to market. The de novo design opens up many new markets by targeting insect challenges that were previously unattainable with naturally occurring proteins, while also optimizing commercial aspects such as higher gross margins, longer shelf life, stability, and resiliency.

“Completing this proof of concept is a major milestone for IBI Ag,” said Arnon Heyman, CEO of IBI Ag. “To the best of our knowledge, this is the first ever de novo protein design platform for bioinsecticides. It is designed to leverage the company’s proprietary IP for targets in insect control. This allows us to discover and validate new proteins based on vast amounts of data which we believe is a game-changer in the industry. This advancement not only demonstrates our commitment to sustainability but also supports farmers in achieving higher yields without compromising the health of ecosystems.”

“IBI Ag’s achievement underscores the strength, depth and significant market potential of the Trendlines portfolio,” commented Haim Brosh CEO of Trendlines.



“We are proud to support companies that turn innovation into real-world impact aligned with industry needs for sustainability and global food security,” added Nitza Kardish, PhD, Trendlines EVP Head of Agrifood.

-The End-

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

This press release has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:

Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990